Registration for a live webinar on 'Gamma-delta T cells for immunotherapy of cancer' is now open.See webinar details
A systems approach to implementation of personalized cancer therapy
Published on April 30, 2017 51 min
A selection of talks on Oncology
Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
- The Norwegian Radium Hospital, Norway
Drug metabolizing enzymes in cancer therapeutics
- Prof. Bhagwat Prasad
- University of Washington, USA
Key considerations for cancer pharmacotherapy 1
- Prof. Christine M. Walko
- H. Lee Moffitt Cancer Center, Tampa, USA
This is Gordon Mills from the MD Anderson Cancer Center where I'm the chair of the Department of Systems Biology, the co-director of the Khalifa Institute for Personalized Cancer Therapy, the director of the Kleberg Center for Molecular Markers, and co-director of Women's Cancer Moonshot. I'm going to present today a systems approach to the implementation of personalized cancer therapy. Some of what I will be presenting would also be characterized as a systematic approach to delivering an improved response for our patients in terms of targeted therapy and immunotherapy.
Today we have an opportunity to characterize patient tumors in the breadth and depth that we had not been able to do even 10 or 15 years ago. This is allowing us to move away from relatively blunt but effective instruments of radiation therapy and chemotherapy to targeting the genetic aberrations that are specific to each patient's cancer using small molecule inhibitors, targeting the genetic aberrations present in the tumors, and immune oncology agents capitalizing on the genomic instability and new antigens that are presented by the tumor. This gives us an opportunity to move away from approaches that generally targeted cellular proliferation and had a limited therapeutic index to capitalizing on the vulnerabilities that occur when a tumor develops. This development of tumors results in changes as in important signaling pathways that leads to a much more limited heterogeneity of the tumor and a much more limited ability to deal with the stress of therapy that we use. I'll come back to that a little bit later.